[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracoscopic-sympathectomy-ets\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracoscopic-sympathectomy-ets":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":5},"100596622","clinical-investigation-of-sympathetic-nerve-width-measurement-in-thoracoscopic-sympathectomy-100596622",false,"NCT07047859","Clinical Investigation of Sympathetic Nerve Width Measurement in Thoracoscopic Sympathectomy","Inclusion Criteria:\n\n1. Diagnosis : Confirmed autonomic nervous dysfunction (including palmar hyperhidrosis, craniofacial hyperhidrosis, or facial blushing).\n2. Age : ≥18 years and ≤55 years.\n3. Cardiopulmonary Function :\n\n   Normal preoperative chest CT scan and electrocardiogram (ECG).\n4. Performance Status : ECOG score (see Attachment 1) of 0-1, indicating good clinical fitness and ability to perform daily activities independently.\n5. Informed Consent : Patients and their families fully understand the study's purpose, procedures, risks, and potential benefits, voluntarily sign the Informed Consent Form, and agree to participate.\n\nExclusion Criteria:\n\n1\\. Abnormal Preoperative ECG :\n\n1. Severe arrhythmias:\n\n   1. Type II second-degree or higher atrioventricular block.\n   2. Symptomatic ventricular arrhythmias.\n   3. Uncontrolled supraventricular arrhythmias (resting heart rate \\>100 bpm). These may cause inadequate cardiac output, hypoperfusion of vital organs, and increased surgical risk.\n2. Myocardial ischemia or infarction:\n\n   1. ECG showing ST-segment elevation\u002Fdepression, T-wave inversion.\n   2. Pathological Q-waves indicating myocardial infarction. 2. Abnormal Chest CT :\n\n1\\) Severe pulmonary infections (e.g., lobar pneumonia, empyema) with symptoms like fever, cough, dyspnea. Surgery increases infection risk and may lead to atelectasis or respiratory failure.\n\n2\\) Pneumothorax or tension pneumothorax:\n\n1. Significant lung collapse causing dyspnea.\n2. Tension pneumothorax requiring immediate chest tube drainage. 3) Pleural effusion (moderate\u002Flarge volume): Causes dyspnea or mediastinal shift; surgery may worsen respiratory function.\n\n   3\\. Hyperthyroidism-induced facial blushing or generalized hyperhidrosis. 4. Anesthesia Contraindications : Allergy to anesthetics or high-risk conditions (severe pulmonary\u002Fcardiac dysfunction).\n\n   5\\. Cognitive\u002FPsychiatric Impairment : Inability to provide informed consent or understand study risks.\n\n   6\\. Non-Compliance with Follow-up : Inability to adhere to postoperative visits.\n\n   7\\. Immunodeficiency Disorders : Severe immunodeficiency, AIDS, or organ transplant history.\n\n   8\\. Frailty\u002FAdvanced Age : Elderly patients with comorbidities or functional decline unfit for surgery.\n\n   9\\. Severe Organ Dysfunction : Cirrhosis, renal failure, or inability to tolerate surgery\u002Frecovery.\n\n   10\\. Active Infections : Under antibiotic treatment for pneumonia, tuberculosis, or bacterial infections.\n\n   11\\. Uncontrolled Diabetes : Poor glycemic control with complications (retinopathy, diabetic foot).\n\n   12\\. Concurrent Clinical Trials : Participation in other interventional studies affecting results.\n\n   13\\. Severe Malnutrition : Significant weight loss or nutritional deficiency increasing anesthesia\u002Fsurgical risks.\n\n   14\\. Hematologic Disorders : Anemia, thrombocytopenia, or coagulopathies affecting hemostasis\u002Frecovery.\n\n   15\\. Severe Chronic Respiratory Failure : Long-term ventilator dependence or tracheostomy.","ALL","18 Years","55 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","This prospective, single-center observational study evaluates the clinical utility of intraoperative sympathetic nerve width measurement during thoracoscopic sympathectomy (ETS) for palmar\u002Fcraniofacial hyperhidrosis (PH\u002FCH) and facial blushing (FF). The study aims to correlate nerve width-measured using a novel Rapid Intraoperative Sympathetic Nerve Width System (RMSNW-OS) (±0.2mm precision)-with surgical outcomes, compensatory sweating rates, patient satisfaction, and 12-month efficacy.\n\nApproximately 1,000 patients (aged 18-55) will undergo standardized ETS at Shanghai First People's Hospital (2025-2029). Objective metrics include thermographic (palmar\u002Fforehead temperature), hemodynamic (HR\u002FBP), biochemical (catecholamines), and Doppler flow measurements. Patient-reported outcomes use diagnosis-specific binary questionnaires and the Hyperhidrosis Disease Severity Scale (HDSS).\n\nStatistical analysis will determine if nerve width predicts treatment response. Innovations include RMSNW-OS standardization and a multidimensional assessment framework to optimize ETS precision and patient quality of life.",[24],"Thoracoscopic Sympathectomy (ETS)","NOT_YET_RECRUITING","2025-06-30",{"date":28,"type":29},"2025-07-02","ACTUAL",{"date":31,"type":20},"2025-07-15",{"date":33,"type":20},"2029-05-31",{"name":35,"class":36},"Tongji University","OTHER"]